Will PGNY's Q1 2025 forecast beat expectations like Q4 2024?

**Progyny's Q1 2025 forecast suggests a positive outlook**, and it is likely to exceed market expectations, here's why:

1. **Consistent Growth Trajectory**: Progyny has demonstrated a consistent growth trajectory in its financial performance. In Q4 2024, the company reported actual EPS of $0.42 and revenue of $298.43 million. For Q1 2025, the estimated EPS is $0.18 with an estimated revenue of $303.5 million. The estimated revenue for Q1 2025 is higher than the actual revenue for Q4 2024, indicating a positive growth expectation.

2. **Analyst Optimism**: Analysts have upgraded Progyny from Neutral to Buy on March 31, 2025, suggesting a bullish outlook. The average one-year price target for Progyny is $27.71, with a range from $23.23 to $35.70, indicating significant upside potential from the current price.
3. **Financial Health and Strategic Moves**: Progyny's financial health, as indicated by a "great performance" in its Financial Health score, and its strategic expansions, including adding new clients and services, suggest a strong foundation for exceeding expectations. Despite challenges from client departures and a slight decrease in female utilization, the company's retention of 99% of its clients and expansion of its partner network are positive indicators.
4. **Historical Performance and Future Guidance**: Progyny's historical performance and future guidance provide a framework for understanding its potential to beat expectations. The company has reported ninth consecutive years of growth, with full-year revenue increasing by 7% to $1.17 billion. For Q1 2025, Progyny sees EPS of $0.44-$0.47 and revenue of $300.00-$318.00 million, which are aligned with the analyst consensus.

In conclusion, considering Progyny's historical performance, analyst optimism, and strategic initiatives, it is reasonable to expect that the company's Q1 2025 forecast will likely beat market expectations, similar to its Q4 2024 performance.